## Management of Patients with Metastatic Prostate Cancer

Anthony Joe\*

Department of Medicine, University of California, California, U.S.A

Corresponding author:ÁŒ}c@[}^ÁR[^ÉkÖ^]æ|c {^}dc[-Á⊤^åå&å}^ÉkW}iç^\+ōic^Á[-ÁŌæ]i-[¦}iæÉkÔæ]i-[¦}iæÉkÛŒÉkÔ {æi|Kĺæ&á}æ]\*|ææ6€ÍÎO@[c {æi|Ek@[{

Received:

Citation: R[^\delige=GGD\Tæ}æ\*^{^}\d[-\du\each^}c\*\, io@\T^cæ\*cæci&\du';[\*cæc^\do\each^\each}&^;\delige=KR\du]&[|\du'\\*\du'\\*\each}\delige=KT\delige=Copyright: © 2022 R[^\delige=KT. This is an open-access article distributed under the terms of the Creative

## Conclusion

The clinical course of individual patients with prostate cancer varies widely and is unpredictable, and the illness has a lengthy history. Deep sequencing technology has made it possible to learn new things about prostate cancer's cistromic and transcriptomic characteristics. From

bedside and molecular imaging methods, our understanding of prostate cancer biology has been significantly improved. It is crucial that we enhance our present the agnostic models, which include our diagnostic methods, treatment approaches, and the medications available to target non-AR signaling.